REGENERON PHARMACEUTICALS, INC. (REGN) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $238.5M (period ending 2008-12-31) to $14.34B (period ending 2025-12-31) — a 27.3% annual pace across 17 year(s) of filed history.
- Net margin turned from a loss (-33.2%) to a 31.4% margin over that same span.
- Across 52 tracked quarters, the strongest was $5.14B (quarter ending 2021-06-30) and the weakest was $90.0M (quarter ending 2009-06-30).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $14.34B | 2025-12-31 | 10-K | 0000872589-26-000008 |
| Operating income | $3.58B | 2025-12-31 | 10-K | 0000872589-26-000008 |
| Net income | $4.50B | 2025-12-31 | 10-K | 0000872589-26-000008 |
| Diluted EPS | $41.48 | 2025-12-31 | 10-K | 0000872589-26-000008 |
| Total assets | $40.56B | 2025-12-31 | 10-K | 0000872589-26-000008 |
| Total liabilities | $9.30B | 2025-12-31 | 10-K | 0000872589-26-000008 |
| Cash & equivalents | $3.12B | 2025-12-31 | 10-K | 0000872589-26-000008 |
| Operating cash flow | $4.98B | 2025-12-31 | 10-K | 0000872589-26-000008 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $4.29B | 2026-06-30 | 10-Q | 0000872589-26-000025 |
| Operating income | $1.29B | 2026-06-30 | 10-Q | 0000872589-26-000025 |
| Net income | $1.30B | 2026-06-30 | 10-Q | 0000872589-26-000025 |
| Diluted EPS | $12.23 | 2026-06-30 | 10-Q | 0000872589-26-000025 |
| Total assets | $41.73B | 2026-06-30 | 10-Q | 0000872589-26-000025 |
| Total liabilities | $10.02B | 2026-06-30 | 10-Q | 0000872589-26-000025 |
| Cash & equivalents | $2.46B | 2026-06-30 | 10-Q | 0000872589-26-000025 |
| Operating cash flow | $1.08B | 2026-03-31 | 10-Q | 0000872589-26-000016 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
Regeneron Pharmaceuticals, Inc. (REGN) operates in the biopharmaceutical sector with a substantial scale, as evidenced by its $14.34 billion revenue and $40.56 billion total assets in the most recent annual filing. The company’s multi-year trajectory reveals consistent growth, with revenues expanding at an impressive 27.3% annual pace over 17 years, from $238.5 million in 2008 to $14.34 billion in 2025. This growth is complemented by a significant improvement in net margin, transitioning from a loss of -33.2% in 2008 to a robust 31.4% in 2025.
In the most recent quarterly filing, REGENERON reported $4.29 billion in revenue and $1.30 billion in net income, reflecting continued strong performance despite a slight dip from the preceding annual peak. The company’s operating cash flow stands at $4.98 billion for the year and $1.08 billion for the most recent quarter, indicating robust liquidity and financial health.
Investors should monitor Regeneron’s ability to sustain this growth trajectory amidst increasing competition in the biopharmaceutical space and potential regulatory hurdles. Additionally, keeping an eye on research and development (R&D) investments will be crucial, as these expenditures are vital for maintaining a pipeline of future products and ensuring long-term success in this capital-intensive industry. The next filing should provide insights into R&D spending trends and any new product approvals or partnerships that could impact future revenue growth.
Source: SEC EDGAR company facts for CIK 0000872589 · filings index